https://onlinelibrary.wiley.com/doi/10.1111/acel.70364
cite:
Taken together, our findings of immune cell benefit on rapamycin treatment in vitro and from analysis of PBMCs from an in vivo study using low-dose rapamycin lead us to conclude that rapamycin at 1 mg/day enhances the resilience of the ageing immune system to DNA damage. Our findings support the initiation of phase 2 double-blind placebo-controlled studies of rapamycin to support healthy immunity and reduce immunosenescence in at-risk older adults.